ClinicaliQ Trial Snapshot
- Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis — Recruiting • Phase III • Oncology • NCT07039916.
- Treatment being tested: IMVT-1402, a novel therapeutic agent, is being evaluated for efficacy, safety and tolerability in adults with generalized myasthenia gravis across mild to severe disease spectrum.
- Patient eligibility: The trial includes adult patients with confirmed mild to severe generalized myasthenia gravis, representing a broad range of disease severity to assess real-world applicability.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
Eligibility Snapshot
- : * Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures. * Have mild to severe gMG by Myasthenia Gravis Foundation of America (MGFA) classification of Class II, III, or IVa at the Screening Visit * Have an MG activities of daily living (MG-ADL) score of ≥ 6 at the Screening Visit and Baseline Visit (Day 1) Additional inclusion criteria are defined in the protocol.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.